A global pandemic has highlighted the world’s reliance on leading pharmaceutical companies and has undeniably brought a host of new expansion opportunities to this industry: new drug developments, more advanced technology, and new globalized markets. Yet, volatile pharma supply pipelines, unpredictable government regulations, and declining R&D efficiency continue to hinder growth for many companies.
To move forward at full force, pharmaceutical and life sciences companies must remain on the cutting edge of their fields and quality tends to be a decision-driving priority. Managing expenses often takes a back seat, and indirect suppliers know this and have seized the opportunity. Fine Tune can help. We work with some of the largest pharma and life sciences companies in the world, and they all have appreciated the value we’ve added for them while they focus on mission-critical priorities. Within one year of partnering with a leading life science company, Fine Tune was able to identify over $500,000 in unnecessary costs and redesign their supplier inventory system to guarantee the cost savings would stick while ensuring adequate supply to keep business running smoothly.